Jiangxi Bio's Hong Kong IPO Prospectus Expires

Stock News
10/13

Jiangxi Biological Products Research Institute Co., Ltd. (Jiangxi Bio) saw its Hong Kong stock exchange IPO prospectus expire on October 11th, six months after its initial submission on April 11th. CICC and CMB International Securities served as joint sponsors for the listing application.

According to the prospectus, citing Frost & Sullivan data, Jiangxi Bio is the largest provider of human tetanus antitoxin (TAT) in both China and globally. Based on 2024 sales volumes, the company holds market shares of 65.8% in China and 36.6% worldwide.

Tetanus antitoxin is an antiserum that provides immediate protection and treatment by neutralizing toxins produced by Clostridium tetani, the bacteria responsible for tetanus infections, thereby preventing and treating tetanus.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10